Stockscreener 앱 받기
9.2304
1.07%
-0.0896
전일 마감가:
$9.32
열려 있는:
$9.18
하루 거래량:
699.04K
Relative Volume:
0.22
시가총액:
$1.47B
수익:
$68.56M
순이익/손실:
$-437.99M
주가수익비율:
-2.9174
EPS:
-3.1639
순현금흐름:
$-396.61M
1주 성능:
-2.74%
1개월 성능:
+17.90%
6개월 성능:
+77.99%
1년 성능:
+32.66%
1일 변동 폭
$9.08
$9.36
1주일 범위
$8.985
$9.85
52주 변동 폭
$4.155
$10.94
비르 바이오테크 Stock (VIR) Company Profile
명칭
Vir Biotechnology Inc
전화
415-906-4324
주소
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
9.22 | 1.49B | 68.56M | -437.99M | -396.61M | -3.1639 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.54 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.00 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
680.44 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.00 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
281.47 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
비르 바이오테크 Stock (VIR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-24 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2025-09-03 | 개시 | Evercore ISI | Outperform |
| 2025-08-27 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-01-29 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-09-08 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-03-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-02-21 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-01-27 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | 개시 | SVB Leerink | Outperform |
| 2022-09-09 | 개시 | Morgan Stanley | Underweight |
| 2022-03-03 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-09-22 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-01-27 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2021-01-20 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-05 | 개시 | BofA Securities | Buy |
| 2020-09-14 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-09-11 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2020-08-20 | 개시 | Needham | Buy |
| 2020-03-19 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2020-03-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-02-27 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-11-14 | 개시 | Robert W. Baird | Neutral |
| 2019-11-05 | 개시 | Barclays | Overweight |
| 2019-11-05 | 개시 | Cowen | Outperform |
| 2019-11-05 | 개시 | Goldman | Buy |
| 2019-11-05 | 개시 | JP Morgan | Overweight |
모두보기
비르 바이오테크 주식(VIR)의 최신 뉴스
These analysts boost their forecasts on Vir Biotechnology - MSN
Why did Vir Biotechnology stock surge 60% after-hours today? - MSN
Henry Schein, Vir Biotechnology, Ultra Clean Holdings and other big stocks moving higher on Tuesday - MSN
Guidance Update: What is the Moat Score of Vir Biotechnology IncPortfolio Value Report & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
VIR News Today | Why did Vir Biotechnology stock go up today? $VIR - MarketBeat
Vir Biotechnology Stock Pre-Market (+0.2%): Ahead of Leerink Conference Presentation - Trefis
Biggest stock movers Tuesday: HIMS, VIR, CLVT, and more - MSN
VIR-5500 Phase 1 trial yields positive data in prostate cancer, Vir Biotechnology asserts - Traders Union
Vanguard Group Inc. Lowers Stock Position in Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology Q4 2025 earnings preview - MSN
HC Wainwright Brokers Boost Earnings Estimates for VIR - MarketBeat
Why Did Vir Biotechnology Stock Surge 60% After-Hours Today? - Stocktwits
Vir Biotechnology Names CEO Marianne De Backer as President - The Globe and Mail
According to the latest filing disclosed by the U.S. Securities and Exchange Commission (SEC), biotechnology company Vir Biotechnology, Inc. has announced a significant personnel appointment. - Bitget
Vir Biotechnology Appoints Marianne De Backer As President In Addition To CEO On March 4, 2026SEC Filing - TradingView
Vir Biotechnology appoints Marianne De Backer as president in addition to CEO on March 4, 2026SEC filing - marketscreener.com
Vir Biotechnology, Inc. Appoints Marianne De Backer as President - marketscreener.com
Vir Biotechnology (NASDAQ:VIR) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
VIR: HC Wainwright & Co. Raises Price Target to $20, Maintains B - GuruFocus
Assessing Vir Biotechnology (VIR) Valuation After Astellas Alliance And VIR-5500 Phase 1 Update - simplywall.st
Vir Biotechnology, Inc. (VIR) Presents at 2026 ASCO Genitourinary Cancers SymposiumSlideshow - Seeking Alpha
VIR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ARCH funds detail 8% Vir Biotechnology (NASDAQ: VIR) stake - Stock Titan
Insider Sell: Vicki Sato Sells 22,000 Shares of Vir Biotechnology Inc (VIR) - GuruFocus
Vir Biotechnology (NASDAQ:VIR) Director Vicki Sato Sells 22,000 Shares - MarketBeat
22,000 Vir Biotechnology (VIR) shares sold under 10b5-1 plan - Stock Titan
VIR (NASDAQ: VIR) files Form 144 for 88,000 pre-IPO shares - Stock Titan
Vir Biotechnology closes $172.5 million public offering of common stock - Investing.com South Africa
Vir Biotechnology Raises Capital Through Public Stock Offering - TipRanks
Vir Biotechnology closes $172.5 million public offering of common stock By Investing.com - Investing.com UK
Vir Biotechnology completes $172.5M follow-on offering, issues 20.29M shares - TradingView
[8-K] Vir Biotechnology, Inc. Reports Material Event | VIR SEC FilingForm 8-K - Stock Titan
Vir Biotechnology Astellas Deal Puts VIR-5500 And Valuation In Focus - Yahoo Finance
Vir Biotechnology (NASDAQ:VIR) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Watch Vir Bio CEO on Cancer Treatment Progress, Potential Deals - Bloomberg
Why Vir Biotechnology (VIR) Is Up 20.2% After Astellas Deal And $150 Million Equity Raise - simplywall.st
Leerink Maintains Outperform on Vir Biotechnology, Inc. (VIR) Feb 2026 - Meyka
Insider Selling: Vir Biotechnology (NASDAQ:VIR) CFO Sells 1,634 Shares of Stock - MarketBeat
Brent Sabatini Sells 1,430 Shares of Vir Biotechnology (NASDAQ:VIR) Stock - MarketBeat
Mark Eisner Sells 1,616 Shares of Vir Biotechnology (NASDAQ:VIR) Stock - MarketBeat
Vir Biotechnology (NASDAQ:VIR) EVP Verneuil Vanina De Sells 3,117 Shares - MarketBeat
Vir Biotechnology Announces Significant Common Stock Offering - TipRanks
Vir Biotechnology prices $150M stock offering at $8.50/share By Investing.com - Investing.com Australia
Vir Biotechnology (NASDAQ:VIR) Director Vicki Sato Sells 42,377 Shares - MarketBeat
Vir Biotechnology (NASDAQ:VIR) CEO Backer Marianne De Sells 14,762 Shares - MarketBeat
Vir Biotechnology (NASDAQ: VIR) plans $141.1M stock sale - Stock Titan
Vir Biotechnology (VIR) to Sell 17.65M Shares; Astellas Collaboration Disclosed - Stock Titan
Vir Biotechnology (VIR) director Sato exercises options and sells 42,377 shares - Stock Titan
[Form 4] Vir Biotechnology, Inc. Insider Trading Activity - Stock Titan
Vir Biotechnology (VIR) CFO executes automatic 10b5-1 share sale for taxes - Stock Titan
비르 바이오테크 (VIR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.42%
1.08%
자본화:
|
볼륨(24시간):